# Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome

> **NCT03337451** · PHASE1,PHASE2 · COMPLETED · sponsor: **Opsona Therapeutics Ltd.** · enrollment: 14 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** OPN-305

## Key facts

- **NCT ID:** NCT03337451
- **Lead sponsor:** Opsona Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-27
- **Primary completion:** 2019-01-10
- **Final completion:** 2019-01-10
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2019-01-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03337451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03337451, "Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03337451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*